-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune thrombocytopenia (ITP) is the most common autoimmune cytopenia in adults and children
Immune thrombocytopenia (ITP) is the most common autoimmune cytopenia in adults and children
The purpose of a foreign study is to evaluate the clinical manifestations and management of primary ITP in very elderly patients (VEPs: age ≥ 80 years) and elderly patients (EPs: age 65-79 years), and to determine risk factors for bleeding at the initial presentation
The purpose of a foreign study is to evaluate the clinical manifestations and management of primary ITP in very elderly patients (VEPs: age ≥ 80 years) and elderly patients (EPs: age 65-79 years), and to determine risk factors for bleeding at the initial presentation Among 541 patients, 184 cases were included: 87 cases in the VEP group and 97 cases in the EP group
9 Severe bleeding is often seen in vep ITP drug exposure, first-line treatment response, need for second-line treatment, continuous development, bleeding occurrence, infection and thrombosis.
Patient characteristics: Patient characteristics:
Bleeding events when the platelet count of the EP group and the VEP group caused immune thrombocytopenia:
Bleeding events caused by immune thrombocytopenia caused by platelet count in EP group and VEP group : Bleeding events when platelet count caused immune thrombocytopenia in EP group and VEP group:Any bleeding in VEP patients, as well as the risk of mucosal bleeding and severe bleeding:
Any bleeding in VEP patients, as well as the risk of mucosal bleeding and severe bleeding: Any bleeding in VEP patients, as well as the risk of mucosal bleeding and severe bleeding:First-line and second-line treatments in the VEP and EP groups:
First-line and second-line treatment of VEP and EP group : First-line and second-line treatment of VEP and EP group:Cumulative incidence of death, bleeding, infection and thrombosis in EP and VEP patient groups:
Cumulative incidence of death, bleeding, infection, and thrombosis in the EP and VEP patient group : Cumulative incidence of death, bleeding, infection, and thrombosis in the EP and VEP patient group:They also found that the severe bleeding in the VEP group did not seem to be related to platelet count, but was highly related to anticoagulant drugs
They also found that the severe bleeding in the VEP group did not seem to be related to platelet count, but was highly related to anticoagulant drugs
, 80-year-old patients with primary ITP and 65-79-year-old ≥ patients have similar performance, management and disease evolution
Original source:
Sokal, A.
Sokal, A.
, de Nadaï, T.
, Maquet, J.
, Comont, T.
, Limal, N.
, Michel, M.
, Beyne-Rauzy, O.
, Godeau, B.
, Adoue, D.
, Mahévas, M.
, Moulis, G.
and (2021), Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry.
Br J Haematol.
https://doi.
org/10.
1111/bjh .
17935.
Leave a message here
